Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3Gastrointestinal 3Genitourinary 2Sarcoma 1NET 1Head & Neck 1Endocrine 1Breast 1

Conditions

Colorectal Neoplasms 2Rectal Neoplasms 1Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × cixutumumab × Gastrointestinal × Clear all
NCT00845039 2018-07-02

FC-4

Eli Lilly and Company

Phase 2 Terminated
4 enrolled 9 charts
Gastrointestinal

Colonic Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00503685 2018-06-06

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

Eli Lilly and Company

Phase 2 Completed
65 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

NCT00906373 2018-06-04

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

Eli Lilly and Company

Phase 2 Completed
47 enrolled 14 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡